BEIJING, Nov. 9, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the hiring of Zhengming Du, Ph.D., as Senior Vice President and Head of Chemistry and Manufacturing Controls (CMC). Dr. Du will be responsible for leading all aspects of CMC activities for our preclinical and clinical projects. His responsibilities include overseeing local and global CMC regulations, assisting in preparation and submission of Investigational New Drug Applications in the United States and New Drug Applications in China, and interacting with the China Food and Drug Administration and the U.S. Food and Drug Administration to ensure all development and registration is in accordance with regulatory requirements.
“Dr. Du is very talented and a strong addition to our manufacturing team. I’m delighted to have him join BeiGene,” said John V. Oyler, CEO of BeiGene. “Dr. Du has over 30 years of academic and pharmaceutical R&D experience, and his proven track record in leadership and execution makes him the ideal choice to lead our CMC strategies to support commercial development of our preclinical and clinical assets in our portfolio.”
Dr. Du joins BeiGene from Roche Pharmaceuticals (China), where he was the Director and Head of Process Research and Synthesis. Previously, Dr. Du was a Vice President of R&D center at Zhejiang Huahai Pharmaceuticals and held Fellow and Leader chemist roles at Novartis in the United States. He received his Ph.D. from Clark University, Massachusetts, United States and his B.Sc. in Chemistry from Nanjing University, China.
“I am excited to join the BeiGene team and to direct the development and implementation of our CMC strategies to help advance our pipeline of immuno-oncology and combination therapeutics,” said Dr. Du. “I look forward to being a key contributor to realize the full potential of our robust portfolio.”
About BeiGene
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 190+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at www.beigene.com.
CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 pr@beigene.com
Help employers find you! Check out all the jobs and post your resume.
